Solving Riddles Through Sequencing

Recruiting now

Conditions studied: Leukemia, Hematologic Malignancy, Rare Diseases, Refractory Leukemia, Refractory Lymphoma, Unknown Primary Tumors

In brief

During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients. This continuous evolution proceeded in parallel to seminal discoveries in basic science such as FISH, PCR and NGS. So far, the current WHO classification serves as reference to diagnostic decision making and is largely based on 5 diagnostic pillars: cytomorphology of peripheral blood and/or bone marrow smears, histology and immunohistochemistry of bone marrow trephine biopsies or lymph nodes, immunophenotyping, chromosome banding analysis supplemented by FISH analysis, molecular genetics including PCR and targeted panel sequencing via NGS. This leads to a swift diagnosis in 90 % of all cases. The leftover 10 % remain a challenge for hematopathologists and clinicians alike and are resolved through interdisciplinary teams in the context of specialized boards. With the advent of high throughput sequencing (mainly WGS and WTS) the possibility of a comprehensive and detailed portrait of the genetic alterations - specifically in challenging cases - has become a realistic alternative to classical methods. In SIRIUS the investigators will prospectively challenge this hypothesis to address the question of how often a better or final diagnosis can be delivered by WGS and/or WTS and if unclear cases can be efficiently resolved.

Key facts

Study ID: NCT05046444
Run by: Munich Leukemia Laboratory
People needed: 100
Starts: 2022-01-19
Expected to finish: 2026-10-01
Last updated by the study team: 2024-12-17

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients having been investigated with a suspected hematological disorder and:
Having unclear diagnosis after internal routine diagnosis
Unusual clinical course
Unusual r/r status or non-responder
Multiple parallel hematological conditions
Difficult/rare therapy associated/secondary neoplasms
Current diagnostic workup is not satisfactory in terms of (1) accuracy (2) clinical behavior
Only samples of patients min. 18 years of age will be used
Material with a minimum of 20% tumor content in bone marrow or peripheral blood sample
Patient´s informed consent

You may not qualify if…

Sample is not fit for state-of-the-art diagnosis, fails initial quality control. For quality insurance we will exclude samples with wrong anticoagulant sent. Samples with damage due to meteorological reasons (freeze-thaw damage or elevated temperature) will be excluded.
Samples with to scarce material jeopardizing routine gold-standard diagnosis will be excluded (tumor content < 20 %).

Where it is running

MLL Munich Leukemia Laboratory — Munich, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.